Buendia Richard, Zambrano Monica
Colsubsidio Centro de Especialistas, Pontificia Universidad Javeriana, Hospital de la Policía, Bogotá, D.C., Colombia.
Colsubsidio Centro de Especialistas, Pontificia Universidad Javeriana, Hospital de la Samaritana, Bogotá, D.C., Colombia.
BMC Res Notes. 2017 Apr 26;10(1):164. doi: 10.1186/s13104-017-2486-z.
Emerging evidence has shown a significant deficit in the control of hypertension (blood pressure <140/90 mmHg) among Hispanics or Latinos in about 65%. This study aims to determine the efficacy of the combination in fixed doses of olmesartan and amlodipine (20/5, 40/5, and 40/10 mg) in hypertensive patients treated in daily clinical practice by Colombian doctors.
This was an observational, retrospective, open-label, multi-center, non-comparative study. The primary outcome was a change in systolic and diastolic blood pressure from the baseline to week 12; the secondary outcome was the proportion of patients achieving a target blood pressure of <140/90 mmHg. Safety and tolerability were also evaluated. For analysis, a student t test was used for paired data, McNemar test, and ANCOVA.
A total of 428 patients were enrolled from 16 centers in Colombia. At 12 weeks, patients' systolic blood pressure decreased in response to all three doses: by 27.75 ± 20.73 mmHg in 20/5 mg, 31.13 ± 22.23 mmHg in 40/5 mg, and 46.96 ± 20.15 mmHg in 40/10 mg (all p < 0.001). Furthermore, the diastolic blood pressure decreased by 14.19 ± 12.89 mmHg in 20/5 mg, 16.25 ± 10.87 mmHg in 40/5 mg, and 24.83 ± 10.41 mmHg in 40/10 mg (all p < 0.001). The percentage of patients achieving target blood pressure was 71.31% in 20/5 mg, 70.16% in 40/5 mg, and 63.33% in 40/10 mg.
This study demonstrates the efficacy of the combination in fixed doses of olmesartan and amlodipine in the treatment of Colombian hypertensive patients.
新出现的证据表明，约65%的西班牙裔或拉丁裔人群在高血压控制（血压<140/90 mmHg）方面存在显著不足。本研究旨在确定在哥伦比亚医生日常临床实践中治疗的高血压患者中，固定剂量的奥美沙坦和氨氯地平（20/5、40/5和40/10毫克）联合用药的疗效。
这是一项观察性、回顾性、开放标签、多中心、非对比研究。主要结局是从基线到第12周收缩压和舒张压的变化；次要结局是达到目标血压<140/90 mmHg的患者比例。还评估了安全性和耐受性。分析时，配对数据采用学生t检验、McNemar检验和协方差分析。
共从哥伦比亚的16个中心招募了428名患者。在第12周时，所有三种剂量均使患者收缩压下降：20/5毫克组下降27.75±20.73 mmHg，40/5毫克组下降31.13±22.23 mmHg，40/10毫克组下降46.96±20.15 mmHg（均p<0.001）。此外，舒张压下降情况为：20/5毫克组下降14.19±12.89 mmHg，40/5毫克组下降16.25±10.87 mmHg，40/10毫克组下降24.83±10.41 mmHg（均p<0.001）。达到目标血压的患者百分比在20/5毫克组为71.31%，40/5毫克组为70.16%，40/10毫克组为63.33%。
本研究证明了固定剂量的奥美沙坦和氨氯地平联合用药在治疗哥伦比亚高血压患者方面的疗效。
